Trial Profile
Consideration of combination therapy with both vorinostat and ultraviolet therapy for cutaneous T-cell lymphoma patients
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Adverse reactions
- 15 Oct 2014 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 01 May 2013 New trial record